Arteriogenesis and Therapeutic Neovascularization
For many years, arteriogenesis, also called collateral formation, has been regarded as being a beneficial process to restore blood flow to distal tissues in occluded arteries. Therefore, it is frequently referred to in relation to therapeutic angiogenesis. Despite the big clinical potential and the...
Saved in:
| Other Authors: | , , , |
|---|---|
| Format: | Book Chapter |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2020
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04751naaaa2201117uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_69256 | ||
| 005 | 20210501 | ||
| 020 | |a books978-3-03936-594-4 | ||
| 020 | |a 9783039365937 | ||
| 020 | |a 9783039365944 | ||
| 024 | 7 | |a 10.3390/books978-3-03936-594-4 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Deindl, Elisabeth |4 edt | |
| 700 | 1 | |a Quax, Paul |4 edt | |
| 700 | 1 | |a Waltenberger, Johannes |4 edt | |
| 700 | 1 | |a Schmitz-Rixen, Thomas |4 edt | |
| 700 | 1 | |a Deindl, Elisabeth |4 oth | |
| 700 | 1 | |a Quax, Paul |4 oth | |
| 700 | 1 | |a Waltenberger, Johannes |4 oth | |
| 700 | 1 | |a Schmitz-Rixen, Thomas |4 oth | |
| 245 | 1 | 0 | |a Arteriogenesis and Therapeutic Neovascularization |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 electronic resource (220 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a For many years, arteriogenesis, also called collateral formation, has been regarded as being a beneficial process to restore blood flow to distal tissues in occluded arteries. Therefore, it is frequently referred to in relation to therapeutic angiogenesis. Despite the big clinical potential and the many promising clinical trials on arteriogenesis and therapeutic angiogenesis, the exact molecular mechanisms involved in the multifactorial processes of arteriogenesis are still not completely understood. A better understanding is needed in order to define successful clinical therapies. In this Special Issue, multiple aspects of arteriogenesis and therapeutic angiogenesis will be addressed, ranging from the role of inflammatory processes and immune cells, to growth factors, microRNAs and environmental factors like hypoxia. Therapeutic angiogenesis will also be discussed in relation to the atherosclerosis and intraplaque angiogenesis in hypoxic lesions, as well as specific forms of arteriogenesis in relation to spinal cord blood supply and aorta surgery. The effects of exercise, a frequently prescribed therapy for PAD patients, on arteriogenesis are also discussed. Overall, the papers in this Special Issue on arteriogenesis and therapeutic angiogenesis provide important new insights in the underlying pathophysiological mechanism of these complex processes and may be helpful to define a successful future intervention directed at therapeutic angiogenesis. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a factor VII activating protease | ||
| 653 | |a HABP2 | ||
| 653 | |a VEGF | ||
| 653 | |a matrigel | ||
| 653 | |a neo-vascularization | ||
| 653 | |a hind limb ischemia | ||
| 653 | |a angiogenesis | ||
| 653 | |a arteriogenesis | ||
| 653 | |a ERK | ||
| 653 | |a endothelial cells | ||
| 653 | |a inflammation | ||
| 653 | |a macrophages | ||
| 653 | |a atherosclerosis | ||
| 653 | |a pericyte | ||
| 653 | |a rAAV | ||
| 653 | |a capillary | ||
| 653 | |a microRNA | ||
| 653 | |a isomiRs | ||
| 653 | |a epitranscriptome | ||
| 653 | |a neovascularization | ||
| 653 | |a A-to-I editing | ||
| 653 | |a m6A | ||
| 653 | |a RNA modifications | ||
| 653 | |a RNA methylation | ||
| 653 | |a lower extremity arterial disease | ||
| 653 | |a peripheral arterial disease | ||
| 653 | |a blood flow restriction | ||
| 653 | |a activity-based benefits | ||
| 653 | |a training effects | ||
| 653 | |a effect mechanism | ||
| 653 | |a hyperoxygenation | ||
| 653 | |a vein graft disease | ||
| 653 | |a vascular biology | ||
| 653 | |a spinal cord ischemia | ||
| 653 | |a paraplegia | ||
| 653 | |a aortic disease | ||
| 653 | |a TAAA | ||
| 653 | |a collateral network | ||
| 653 | |a paraspinous compartment | ||
| 653 | |a NO | ||
| 653 | |a NOTCH | ||
| 653 | |a innate immunity | ||
| 653 | |a mast cell | ||
| 653 | |a GH and eNOS | ||
| 653 | |a IGF-I | ||
| 653 | |a oxidative stress and arterial inflammation | ||
| 653 | |a vascular homeostasis | ||
| 653 | |a GHAS trial | ||
| 653 | |a collateral artery growth | ||
| 653 | |a SMC proliferation | ||
| 653 | |a potassium channel | ||
| 653 | |a KV1.3 | ||
| 653 | |a KCa3.1 | ||
| 653 | |a FGFR-1 | ||
| 653 | |a Egr-1 | ||
| 653 | |a PDFG-R | ||
| 653 | |a αSM-actin | ||
| 653 | |a TLR2/6 | ||
| 653 | |a femoral artery ligation | ||
| 653 | |a blood flow recovery | ||
| 653 | |a collateral growth | ||
| 653 | |a VHL loss of function | ||
| 653 | |a microRNA-212/132 | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/3044 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/69256 |7 0 |z DOAB: description of the publication |